文献速递肿瘤 PET/CT核素与放射性配体治疗

您了解您的PSMA示踪剂吗?不同PSMA配体生物分布的可变性及其对PSMA靶向治疗前定义PSMA阳性的潜在影响

Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy.
PubMed 文献 · EJNMMI Res · 2025-01-10

本研究在生化复发前列腺癌患者中个体内比较多种18F标记PSMA配体与68Ga-PSMA-11在肝脏、腮腺和脾脏的摄取及肿瘤-本底比(TBR)。不同示踪剂本底活性差异导致TBR变化,以肝脏为参考时[18F]F-DCFPyL与68Ga-PSMA-11相当,而[18F]F-PSMA-1007和[18F]F-JK-PSMA-7显著更低。作者认为使用替代18F标记示踪剂可能高估或低估患者适合治疗的程度。

要点

  • 以肝脏为参考时,[18F]F-DCFPyL的TBR与68Ga-PSMA-11相当,[18F]F-PSMA-1007和[18F]F-JK-PSMA-7显著更低。
  • 以腮腺为参考时,[18F]F-DCFPyL的TBR显著更高,[18F]F-PSMA-1007和[18F]F-JK-PSMA-7相当。
  • 以脾脏为参考时,[18F]F-JK-PSMA-7相当,[18F]F-DCFPyL显著更高、[18F]F-PSMA-1007显著更低。

核心结论

  • 不同PSMA-PET示踪剂具有不同的生物分布模式,导致肝脏、腮腺和脾脏等参考器官的肿瘤-本底比(TBR)存在差异。
  • 目前PSMA靶向放射性配体治疗的患者选择基于以肝脏为参考区域的[68Ga]Ga-PSMA-11-PET半定量方法,使用替代18F标记示踪剂可能导致对患者适合治疗程度的高估或低估。
  • 作者认为这凸显了全面理解示踪剂特异性摄取行为差异对于准确判断PSMA表达水平的重要性。
  • 作者指出本研究患者队列处于较早疾病阶段,这些发现对晚期患者的普遍适用性仍不清楚,需要进一步研究。

研究设计与样本

  • 研究在生化复发前列腺癌患者中个体内比较不同18F标记PSMA配体与68Ga-PSMA-11的摄取,患者作为个体化诊断方法的一部分接受了双次PSMA-PET检查。

主要发现

  • 以肝脏为参考器官的TBR(TBRliver)中,[18F]F-DCFPyL-PET与[68Ga]Ga-PSMA-11-PET相当,而[18F]F-PSMA-1007-PET和[18F]F-JK-PSMA-7-PET显著更低。
  • 以腮腺为参考的TBR(TBRparotidgland)中,[18F]F-DCFPyL-PET显著更高,而[18F]F-PSMA-1007-PET和[18F]F-JK-PSMA-7-PET相当。
  • 以脾脏为参考的TBR(TBRspleen)中,[18F]F-JK-PSMA-7-PET相当,而[18F]F-DCFPyL-PET显著更高、[18F]F-PSMA-1007-PET显著更低。
  • 补充的Bland-Altman分析显示,[18F]F-DCFPyL-PET在TBRparotidgland中偏倚较低,而其他示踪剂在TBRliver和TBRspleen中的显著差异导致偏倚较高。

局限性

  • 本研究患者队列处于较早疾病阶段,这些发现对晚期患者的普遍适用性仍不清楚,需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In clinical practice, several radiopharmaceuticals are used for PSMA-PET imaging, each with distinct biodistribution patterns. This may impact treatment decisions and outcomes, as eligibility for PSMA-directed radioligand therapy is usually assessed by comparing tumoral uptake to normal liver uptake as a reference. In this study, we aimed to compare tracer uptake intraindividually in various reference regions including liver, parotid gland and spleen as well as the respective tumor-to-background ratios (TBR) of different 18F-labeled PSMA ligands to today's standard radiopharmaceutical 68Ga-PSMA-11 in a series of patients with biochemical recurrence of prostate cancer who underwent a dual PSMA-PET examination as part of an individualized diagnostic approach. RESULTS: Differences in background activity among different PSMA-PET tracers lead to variations in tumor-to-background ratios (TBR). In [18F]F-DCFPyL-PET, TBR with the liver as the reference organ (TBRliver) was comparable to [68Ga]Ga-PSMA-11-PET, while [18F]F-PSMA-1007-PET and [18F]F-JK-PSMA-7-PET showed significantly lower values. Using the parotid gland as the reference (TBRparotidgland), [18F]F-DCFPyL-PET exhibited significantly higher values, whereas [18F]F-PSMA-1007-PET and [18F]F-JK-PSMA-7-PET were comparable. For the spleen (TBRspleen), [18F]F-JK-PSMA-7-PET was comparable, but [18F]F-DCFPyL-PET and [18F]F-PSMA-1007-PET showed significantly higher and lower values, respectively. An additional Bland-Altman analyses revealed low bias for [18F]F-DCFPyL-PET in TBRparotidgland, whereas significant differences in TBRliver and TBRspleen for the other tracers resulted in higher bias. CONCLUSION: Different PSMA-PET tracers exhibit distinct biodistribution patterns, leading to variations in tumor-to-background ratios (TBR) in reference organs such as the liver, parotid gland, and spleen. Patient selection for PSMA-directed radioligand therapy is currently based on a semiquantitative approach using the liver as a reference region in [68Ga]Ga-PSMA-11-PET. Thus, the use of alternative [18F]-labeled tracers may result in under- or overestimation of a patient's suitability for therapy. This highlights the importance of a comprehensive understanding of the differences in tracer-specific uptake behavior for accurate decisions regarding PSMA-expression levels. However, as the patient cohort in this study is at earlier disease stages, the generalizability of these findings to later-stage patients remains unclear and requires further investigation.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Heilinger J, Roth KS, Weis H, et al. Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy. EJNMMI Res. 2025. PMID: 39792324. doi:10.1186/s13550-024-01190-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。